IN8bio, Inc. (INAB) stock
Close on Nov 12, 2026Market cap $8.09MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $8.09M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.57
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$19.41M
- EPS, diluted
- -$1.45
- Book value per share
- $0.73
- Diluted shares
- 19M
Trading
- Next earnings
- Mar 11, 2027 (estimated, during market hours)
- Previous close
- $0.87
- Open
- $0.88
- Day's range
- $0.81 – $0.88
- Volume
- 16,064
- Average volume (20 days)
- 35,660
- Beta (5 years)
- 1.38
- 52-week range
- $0.80 – $2.73
- RSI (14 days)
- 34.9
- Volatility (1 year)
- 86.8%
- Relative volume
- 0.31×
- WACC
- 11.8%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | INAB | S&P 500 | Difference | INAB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -33.3% | -2.7% | −30.6 pts | ||
| 3 months | -17.8% | -1.7% | −16.1 pts | ||
| Year to date | -64.9% | +11.9% | −76.8 pts | ||
| 1 year | -51.7% | +12.0% | −63.7 pts | ||
| 3 years | -97.4% | +78.2% | −175.5 pts | -70.3% | +21.2% |
| 5 years | -99.7% | +73.2% | −172.9 pts | -68.2% | +11.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases IN8bio filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- News
About IN8bio
Biological Products, (No Diagnostic Substances)
IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers. The company develops ex vivo expanded, activated, and genetically engineered gamma-delta T cell therapies using its DeltEx platform to treat cancer and autoimmune diseases. Its therapeutic programs evaluate allogeneic, autologous, and stem-cell-derived approaches, as well as T cell engagers designed to selectively direct gamma-delta T cells against target cells. The company does not currently have commercial products and develops its treatments to serve patients suffering from hematologic cancers, solid tumors, and autoimmune conditions.
Company profile, executives and historyIN8bio stock: common questions
What is IN8bio's stock price?
INAB closed at $0.82 on Nov 12, 2026, down 5.90% on the day. Over the past 52 weeks it traded between $0.80 and $2.73.
What is IN8bio's market cap?
IN8bio was worth $8.09M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is INAB's P/E ratio?
IN8bio lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.45), so it has no meaningful P/E ratio.
Does IN8bio pay a dividend?
No. IN8bio has not paid a cash dividend over the last twelve months.
When does IN8bio report earnings next?
IN8bio is expected to report Q4 FY2026 results on Mar 11, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has INAB stock performed over the past year?
Including dividends, INAB returned -51.7% over the past year, against +12.0% for the S&P 500.
Who are IN8bio's competitors?
Companies most similar to IN8bio by business, industry and size include ESLA, INKT, IPSC, CERO, TCRX.
See a number that looks wrong?